Clavis Pharmas NOK 129 million Private Placement approved at
Extraordinary General Meeting>
Clavis Pharmas NOK 129 million Private Placement approved at Extraordinary General Meeting
(Thomson Reuters ONE) - Oslo, Norway, 15 July 2009. Clavis Pharma ASA (OSE: CLAVIS) announcesthat all items proposed to shareholders at its Extraordinary GeneralMeeting held today in Oslo were resolved according the Board'sproposal.It was resolved to issue 10,750,000 new shares, each with a par valueof NOK 1.00 at a price of NOK 12.00 per share, through a privateplacement directed at existing shareholders, as well as newinstitutional investors, raising gross proceeds of NOK 129 million.It was also resolved to conduct a subsequent repair offering of up to650,000 shares each with a par value of NOK 1.00, at a subscriptionprice of NOK 12.00 per share. Eligible shareholders in Clavis Pharmaas of 25 June 2009 that were not allocated new shares in the PrivatePlacement shall receive one subscription right per 4.284582 sharesheld on 25 June in the repair offering. The closing date for thesubscription period in the Repair Offering is14 August 2009. The subscription rights will not be tradable and willtherefore not be listed on Oslo Børs.For further information please refer to the minutes of theExtraordinary General Meeting attached, which are available atwww.clavispharma.com/News & Events/2009 Press releasesContactGeir Christian Melen, CEOOffice : +47 24 11 09 65Mobile : +47 91 30 29 65E-mail : geir.christian.melen(at)clavispharma.comGunnar Manum, CFOOffice : +47 24 11 09 71Mobile : +47 95 17 91 90E-mail : gunnar.manum(at)clavispharma.comFor international press enquiries:Mark Swallow / Nina Enegren / David DibleCitigate Dewe RogersonOffice : +44 207 282 2948E-mail : clavispharma(at)citigatedr.co.ukAbout Clavis PharmaClavis Pharma ASA is an oncology focused pharmaceutical company usingits proprietary Lipid Vector Technology (LVT) platform to create NewChemical Entities (NCEs), by significantly improving alreadyestablished drugs. The improvements are achieved by chemicallybinding specific unsaturated lipids to existing, and well understood,approved pharmaceuticals. Data generated suggests the resultingpatentable NCEs offer improved efficacy and reduced side effectsthrough enhanced pharmacokinetic properties, greater tissuepenetration and, in many cases, additional modes of action.Clavis Pharma's objective is to develop its drug candidates untilsignificant value has been created and proof of principle in man hasbeen shown. For further clinical development and commercialisation ofthe products, Clavis Pharma will enter into strategic partnershipswith established pharmaceutical or biotech companies. The company'sproduct portfolio includes four new cancer drugs: Elacytarabine is inClinical Phase II, Intravenous CP-4126 is in Clinical Phase II, OralCP-4126 in Phase I, and CP-4200 is in preclinical development.Results indicate that these products have promising potential forseveral cancer indications within solid tumours and leukaemia.The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange(ticker: CLAVIS). Additional information on Clavis Pharma can befound at: http://www.clavispharma.com/.DisclaimerThe information contained herein shall not constitute an offer tosell or the solicitation of an offer to buy, nor shall there be anysale of the securities referred to herein in any jurisdiction inwhich such offer, solicitation or sale would be unlawful prior toregistration, exemption from registration or qualification under thesecurities laws of any such jurisdiction.This news release contains forward-looking statements and forecastsbased on uncertainty, since they relate to events and depend oncircumstances that will occur in the future and which, by theirnature, will have an impact on results of operations and thefinancial condition of Clavis Pharma. There are a number of factorsthat could cause actual results and developments to differ materiallyfrom those expressed or implied by these forward-looking statements.Theses factors include, among other things, risks associated withtechnological development, the risk that research & development willnot yield new products that achieve commercial success, the impact ofcompetition, the ability to close viable and profitable businessdeals, the risk of non-approval of patents not yet granted anddifficulties of obtaining relevant governmental approvals for newproducts.No expressed or implied representations or warranties are givenconcerning Clavis Pharma or the accuracy or completeness of theinformation or projections provided herein, and no claims shall bemade by the recipient hereof by virtue of this Information Memorandumor the information or projections contained herein. Anyrepresentations or warranties made to an investor in Clavis Pharmawill be subject to separate sale and purchase agreements to benegotiated between the parties.Clavis Pharma(TM) is a registered trademark of Clavis Pharma ASA.http://hugin.info/136972/R/1329021/313577.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Bereitgestellt von Benutzer: hugin
" alt="Disclosure of Short Position - GKN Plc>">
" alt="Net Asset Value(s)>">Datum: 15.07.2009 - 16:51 Uhr
Sprache: Deutsch
News-ID 3594
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 228 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clavis Pharmas NOK 129 million Private Placement approved at
Extraordinary General Meeting>"
steht unter der journalistisch-redaktionellen Verantwortung von
Clavis Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
